# KRYS catalysts: Krystal Biotech, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/krys/catalysts

> Krystal Biotech, Inc. (KRYS) has 4 upcoming catalysts. The next is the KB803 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Krystal Biotech, Inc. |
| Ticker | KRYS (Nasdaq) |
| SEC CIK | 1711279 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/krys |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [Vyjuvek (beremagene geperpavec) FDA approval](https://sec-api.dev/pdufa/beremagene-geperpavec) | KRYS | dystrophic epidermolysis bullosa | completed, approved | "•our commercialization plans in the United States, the European Union ("EU"), Japan, and elsewhere for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt), which was approved by the U.S. Food and Drug Administration ("FDA") in May 2023, the European Commission ("EC") in April 2025, and Japan's Ministry of Health, Labour and Welfare ("MHLW") in July 2025 for the treatment of dystrophic epidermolysis bullosa ("DEB");" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm)) |
| Jul 2023 | [KB407 trial start](https://sec-api.dev/pdufa/kb407) | KRYS | CF, regardless of their underlying genotype | completed | "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study, a multicenter, dose-escalation trial of KB407 in patients with CF that included molecular assessments of CFTR delivery and expression in the third and highest dose cohort." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm)) |
| Feb 2024 | [KB408 trial start](https://sec-api.dev/pdufa/kb408) | KRYS | with AATD | completed | "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm)) |
| Nov 2024 | [KB304 trial start](https://sec-api.dev/pdufa/kb304) | KRYS | wrinkles | completed | "•In November 2024, Jeune Aesthetics dosed the first subject in an ongoing, randomized and placebo-controlled Phase 1 study PEARL-2 evaluating its second clinical-stage investigational aesthetic product KB304 for the treatment of wrinkles." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/a4q24exhibit991pr.htm)) |
| May 6, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, May 6, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/a1q25exhibit991pr.htm)) |
| Jun 2025 | [KB803 trial start](https://sec-api.dev/pdufa/kb803) | KRYS |  | completed | "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm)) |
| 2H 2025 | [KB304 topline data readout](https://sec-api.dev/pdufa/kb304) | KRYS |  | scheduled | "We expect to enroll up to 21 subjects in PEARL-2, randomized 2:1 to KB304 or placebo, and report top-line results from the study in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000008/krys-20241231.htm)) |
| 2H 2025 | [KB408 interim data readout](https://sec-api.dev/pdufa/kb408) | KRYS |  | scheduled | "Based on this promising initial data, the Company has simultaneously expanded Cohort 2 and opened Cohort 3 of SERPENTINE-1 for more comprehensive molecular assessments at both dose levels and expects to report results from both cohorts in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/a4q24exhibit991pr.htm)) |
| July 9, 2025 | [KB801 trial start](https://sec-api.dev/pdufa/kb801) | KRYS | neurotrophic keratitis | completed | "On July 9, 2025, Krystal Biotech, Inc. (the "Company") issued a press release announcing the first patient dosed in the Company's Phase 1/2 trial of KB801 for the treatment of neurotrophic keratitis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/krys-20250709.htm)) |
| August 4, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, August 4, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/a2q25exhibit991pr.htm)) |
| late 2025 | [KB407 interim data readout](https://sec-api.dev/pdufa/kb407) | KRYS | CF, regardless of their underlying genotype | scheduled | "•The Company continues to enroll in Cohort 3 of CORAL-1, the Company's multi-center, dose escalation study evaluating KB407 in patients with CF, regardless of their underlying genotype, and expects to provide an interim data readout for Cohort 3 patients before year end." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| Q4 2025 | [KB301 trial start](https://sec-api.dev/pdufa/kb301) | KRYS |  | scheduled | "Based on these Phase 1 results, Jeune selected treatment of the dynamic wrinkles of the décolleté for advanced clinical development and expects to initiate a randomized, placebo-controlled Phase 2 study evaluating KB301 in this indication in the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000044/krys-20250331.htm)) |
| November 3, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, November 3, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| 2026 | [KB105 trial start](https://sec-api.dev/pdufa/kb105) | KRYS | TGM1-deficient lamellar ichthyosis in pediatric patients in 2026 | scheduled | "•The Company expects to initiate the Phase 2 portion of its KB105 Phase 1/2 JADE-1 trial evaluating KB105 for the treatment of TGM1-deficient lamellar ichthyosis in pediatric patients in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/a2q25exhibit991pr.htm)) |
| 1H 2026 | [KB304 trial start](https://sec-api.dev/pdufa/kb304) | KRYS |  | scheduled | "•Jeune Aesthetics, Inc. (Jeune), a wholly-owned subsidiary of the Company, remains on track to initiate a Phase 2 study of its lead program KB304 in 1H 2026 following feedback from the FDA on Jeune's validated décolleté-specific photonumeric scale and Phase 2 study design in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| 1H 2026 | [KB408 interim data readout](https://sec-api.dev/pdufa/kb408) | KRYS |  | scheduled | "•The Company continues to enroll in repeat dose Cohort 2B of SERPENTINE-1, the Company's open label dose escalation study evaluating KB408 in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype, and expects to report interim data for this cohort in 1H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| January 11, 2026 | [Vyjuvek (beremagene geperpavec) earnings report](https://sec-api.dev/pdufa/beremagene-geperpavec) | KRYS |  | completed | "PITTSBURGH, January 11, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/jpm2026preannouncementprex.htm)) |
| February 17, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, February 17, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/a4q25exhibit991pr.htm)) |
| 2H 2026 | [KB111 trial start](https://sec-api.dev/pdufa/kb111) | KRYS | HHD in 2H 2026 | scheduled | "The Company expects to complete development and validation of the scale in 1H 2026 and initiate a registrational study evaluating KB111 for the treatment of HHD in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/a4q25exhibit991pr.htm)) |
| 2H 2026 | [KB707 interim data readout](https://sec-api.dev/pdufa/kb707) | KRYS |  | scheduled | "The Company expects to report interim efficacy data and potential registrational study plans in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| August 3, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, August 3, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company" or "Krystal") (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)) |
| late 2026 | [KB801 topline data readout](https://sec-api.dev/pdufa/kb801) | KRYS |  | delayed | "Top line data from the study is expected before the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/jpm2026preannouncementprex.htm)) |
| Q4 2026 | [KB803 topline data readout](https://sec-api.dev/pdufa/kb803) | KRYS |  | scheduled | "The Company's registrational, intra-patient, double-blind, de-centralized, placebo-controlled study (IOLITE) with crossover design evaluating KB803 for the treatment and prevention of corneal abrasions in DEB patients was fully enrolled in April and is on track for a top-line data readout in 4Q 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)) |
| November 2, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, November 2, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company" or "Krystal") (NASDAQ: KRYS) today reported financial results for the third quarter ended September 30, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/exhibit991-3q26pressrelease.htm)) |
| December 2026 | [KB803 primary completion](https://sec-api.dev/pdufa/kb803) | KRYS |  | scheduled | "NCT07016750 (A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Krystal Biotech, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07016750)) |
| 2027 | [KB304 trial start](https://sec-api.dev/pdufa/kb304) | KRYS |  | scheduled | "Jeune Aesthetics, Inc., a wholly owned subsidiary of the Company, expects to initiate a Phase 2 study of its lead program KB304 in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/exhibit991-3q26pressrelease.htm)) |
| 2027 | [KB801 topline data readout](https://sec-api.dev/pdufa/kb801) | KRYS |  | scheduled | "The Company now expects to complete enrollment of approximately 60 patients in EMERALD-1 and report top-line results in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/exhibit991-3q26pressrelease.htm)) |
| Feb 2027 | [KB803 topline data readout](https://sec-api.dev/pdufa/kb803) | KRYS |  | scheduled | "We expect the last patient visit for IOLITE in February 2027 with top-line results reported shortly thereafter." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm)) |

## Drugs

- [Vyjuvek (beremagene geperpavec)](https://sec-api.dev/pdufa/beremagene-geperpavec): dystrophic epidermolysis bullosa
- [KB105](https://sec-api.dev/pdufa/kb105): tgm1-deficient lamellar ichthyosis in pediatric patients in 2026, tgm1-deficient li in pediatric patients in 2026, tgm1-deficient li in 2026
- [KB111](https://sec-api.dev/pdufa/kb111): hhd in 2h 2026
- [KB301](https://sec-api.dev/pdufa/kb301): 
- [KB304](https://sec-api.dev/pdufa/kb304): wrinkles, wrinkles of the décolleté, in july 2025, we
- [KB407](https://sec-api.dev/pdufa/kb407): cf, regardless of their underlying genotype, with cf
- [KB408](https://sec-api.dev/pdufa/kb408): with aatd
- [KB707](https://sec-api.dev/pdufa/kb707): 
- [KB801](https://sec-api.dev/pdufa/kb801): neurotrophic keratitis
- [KB803](https://sec-api.dev/pdufa/kb803): Dystrophic Epidermolysis Bullosa

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/krys/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KRYS catalysts: Krystal Biotech, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/krys/catalysts

```bibtex
@misc{secapidev_companies_krys_catalysts_20261116,
  title        = {KRYS catalysts: Krystal Biotech, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/krys/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_krys_catalysts_20261116","title":"KRYS catalysts: Krystal Biotech, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/krys/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
